These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32597258)

  • 41. Promoter methylation status of VEGF receptor genes: a possible epigenetic biomarker to anticipate the efficacy of intracellular-acting VEGF-targeted drugs in cancer cells.
    Kim J; Hwang J; Jeong H; Song HJ; Shin J; Hur G; Park YW; Lee SH; Kim J
    Epigenetics; 2012 Feb; 7(2):191-200. PubMed ID: 22395469
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tyrosine kinase inhibitors of VEGF receptors: clinical issues and remaining questions.
    van Cruijsen H; van der Veldt A; Hoekman K
    Front Biosci (Landmark Ed); 2009 Jan; 14(6):2248-68. PubMed ID: 19273199
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The clinical application of fruquintinib on colorectal cancer.
    Chen Z; Jiang L
    Expert Rev Clin Pharmacol; 2019 Aug; 12(8):713-721. PubMed ID: 31177854
    [No Abstract]   [Full Text] [Related]  

  • 44. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
    Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
    J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Angiogenesis and hypertension: the dual role of anti-hypertensive and anti-angiogenic therapies.
    Ferroni P; Della-Morte D; Palmirotta R; Rundek T; Guadagni F; Roselli M
    Curr Vasc Pharmacol; 2012 Jul; 10(4):479-93. PubMed ID: 22272903
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cardiovascular Toxicities with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of 77 Randomized Controlled Trials.
    Li J; Gu J
    Clin Drug Investig; 2018 Dec; 38(12):1109-1123. PubMed ID: 30327999
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The novel VEGF receptor/MET-targeted kinase inhibitor TAS-115 has marked in vivo antitumor properties and a favorable tolerability profile.
    Fujita H; Miyadera K; Kato M; Fujioka Y; Ochiiwa H; Huang J; Ito K; Aoyagi Y; Takenaka T; Suzuki T; Ito S; Hashimoto A; Suefuji T; Egami K; Kazuno H; Suda Y; Nishio K; Yonekura K
    Mol Cancer Ther; 2013 Dec; 12(12):2685-96. PubMed ID: 24140932
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cytotoxicity of VEGF(121)/rGel on vascular endothelial cells resulting in inhibition of angiogenesis is mediated via VEGFR-2.
    Mohamedali KA; Ran S; Gomez-Manzano C; Ramdas L; Xu J; Kim S; Cheung LH; Hittelman WN; Zhang W; Waltenberger J; Thorpe PE; Rosenblum MG
    BMC Cancer; 2011 Aug; 11():358. PubMed ID: 21849059
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Early Actions of Anti-Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Drugs on Angiogenic Blood Vessels.
    Sitohy B; Chang S; Sciuto TE; Masse E; Shen M; Kang PM; Jaminet SC; Benjamin LE; Bhatt RS; Dvorak AM; Nagy JA; Dvorak HF
    Am J Pathol; 2017 Oct; 187(10):2337-2347. PubMed ID: 28736316
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vascular Cardio-Oncology: Vascular Endothelial Growth Factor inhibitors and hypertension.
    Versmissen J; Mirabito Colafella KM; Koolen SLW; Danser AHJ
    Cardiovasc Res; 2019 Apr; 115(5):904-914. PubMed ID: 30726882
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Recent advances in antiangiogenic agents with VEGFR as target.
    Zhang J; Shan Y; Pan X; He L
    Mini Rev Med Chem; 2011 Oct; 11(11):920-46. PubMed ID: 21762098
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors.
    Lacal PM; Graziani G
    Pharmacol Res; 2018 Oct; 136():97-107. PubMed ID: 30170190
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel VEGF signalling inhibitors: how helpful are biomarkers in their early development?
    Wood J; Scott E; Thomas AL
    Expert Opin Investig Drugs; 2009 Nov; 18(11):1701-14. PubMed ID: 19877763
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects.
    Kappers MH; van Esch JH; Sleijfer S; Danser AH; van den Meiracker AH
    J Hypertens; 2009 Dec; 27(12):2297-309. PubMed ID: 19680138
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antiangiogenesis, anti-VEGF(R) and outlook.
    Petersen I
    Recent Results Cancer Res; 2007; 176():189-99. PubMed ID: 17607926
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anti-Angiogenics: Current Situation and Future Perspectives.
    Zirlik K; Duyster J
    Oncol Res Treat; 2018; 41(4):166-171. PubMed ID: 29562226
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Radiolabeled small molecule inhibitors of VEGFR - recent advances.
    Kniess T
    Curr Pharm Des; 2012; 18(20):2867-74. PubMed ID: 22571655
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis.
    Schomber T; Zumsteg A; Strittmatter K; Crnic I; Antoniadis H; Littlewood-Evans A; Wood J; Christofori G
    Mol Cancer Ther; 2009 Jan; 8(1):55-63. PubMed ID: 19139113
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An updated patent review of VEGFR-2 inhibitors (2017-present).
    Farghaly TA; Al-Hasani WA; Abdulwahab HG
    Expert Opin Ther Pat; 2021 Nov; 31(11):989-1007. PubMed ID: 34043477
    [No Abstract]   [Full Text] [Related]  

  • 60. Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers.
    Mittal K; Koon H; Elson P; Triozzi P; Dowlati A; Chen H; Borden EC; Rini BI
    Cancer Biol Ther; 2014 Aug; 15(8):975-81. PubMed ID: 24842548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.